Ephedra-containing dietary supplement across-the-board label warning suggested by FDA.

EPHEDRA SUPPLEMENT ACROSS-THE-BOARD LABEL WARNING STATEMENT would be required for all dietary supplements containing ephedrine alkaloids under a June 4 FDA proposed rule. The warning statement advises consumers to consult a "health care provider" before using ephedrine alkaloid-containing products if they are pregnant or nursing or have: heart disease; thyroid disease; diabetes; high blood pressure; depression or other psychiatric condition; glaucoma; difficulty in urinating; prostate enlargement; or a seizure disorder.